APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls

Oncotarget

Volumn 6, Issue 29, 2015, Pages 26663-26674

  Sampedro, Frederic ^a,b   Vilaplana, Eduard ^a,b   de Leon, Mony J ^c   Alcolea, Daniel ^a,b   Pegueroles, Jordi ^a,b   Montal, Victor ^a,b   Carmona Iragui, María ^a,b   Sala, Isabel ^a,b   Sánchez Saudinos, María Belén ^a,b   Antón Aguirre, Sofía ^a,b   Morenas Rodríguez, Estrella ^a,b   Camacho, Valle ^a   Falcón, Carles ^d,f   Pavía, Javier ^e,f   Ros, Domènec ^d,f   Clarimón, Jordi ^a,b   Blesa, Rafael ^a,b   Lleó, Alberto ^a,b   Fortea, Juan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Aging; Alzheimer's disease; APOE; Gerotarget; MRI; PET FDG

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; APOLIPOPROTEIN E4;

AGED; ALLELE; APOE GENE; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN REGION; BRAIN STRUCTURE; CENTRAL NERVOUS SYSTEM FUNCTION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); CORTICAL THINNING; CROSS-SECTIONAL STUDY; DRUG UPTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SEX DIFFERENCE; AGING; ALZHEIMER DISEASE; ATROPHY; BRAIN; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HETEROZYGOTE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; ATROPHY; BIOMARKERS; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEALTHY VOLUNTEERS; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SEX FACTORS;

EID: 84944463618     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5185     Document Type: Article

References (38)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer,'s disease in late onset families. Science. 1993; Aug 261:921-3.
2. Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013; Feb 9:106-18.
3. Liu Y, Yu J-T, Wang H-F, Han P-R, Tan C-C, Wang C, Meng X-F, Risacher SL, Saykin AJ, Tan L. APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2015; May 86:127-34.
4. Reinvang I, Espeseth T, Westlye LT. APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease. Neurosci. Biobehav. Rev. 2013; May 37:1322-1335.
5. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. BiolPsychiatry. 2004; Nov 56:670-6.
6. Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. AnnNeurol. 2014; Apr 75:563-73.
7. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. AnnNeurol. 2010; Mar 67:308-16.
8. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 1996; Mar 334:752-8.
9. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U. S. A. 2005; Jun 102:8299-302.
10. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 2004; Jan 101:284-9.
11. Corder EH, Jelic V, Basun H, Lannfelt L, Valind S, Winblad B, Nordberg A. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. ArchNeurol. 1997; Mar 54:273-7.
12. Hirono N, Mori E, Yasuda M, Imamura T, Shimomura T, Hashimoto M, Tanimukai S, Kazui H, Yamashita H. Lack of effect of apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 1999; Jan 11:66-70.
13. Samuraki M, Matsunari I, Chen W-P, Shima K, Yanase D, Takeda N, Matsuda H, Yamada M. Glucose metabolism and gray-matter concentration in apolipoprotein E e4 positive normal subjects. NeurobiolAging. 2012; Oct 33:2321-3.
14. Cherbuin N, Leach LS, Christensen H, Anstey KJ. Neuroimaging and APOE genotype: a systematic qualitative review. Dement. Geriatr. Cogn. Disord. 2007; Jan 24:348-62.
15. Novak NM, Stein JL, Medland SE, Hibar DP, Thompson PM, Toga AW. EnigmaVis: online interactive visualization of genome-wide association studies of the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) consortium. Twin Res. Hum. Genet. 2012; Jun 15:414-8.
16. Espeseth T, Westlye LT, Fjell AM, Walhovd KB, Rootwelt H, Reinvang I. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. NeurobiolAging. 2008; Mar 29:329-340.
17. Espeseth T, Westlye LTL, Walhovd KKB, Fjell AM, Endestad T, Rootwelt H, Reinvang I. Apolipoprotein E e4-related thickening of the cerebral cortex modulates selective attention. NeurobiolAging. 2012; Mar 33:304-322.e1.
18. Filippini N, Ebmeier KP, MacIntosh BJ, Trachtenberg AJ, Frisoni GB, Wilcock GK, Beckmann CF, Smith SM, Matthews PM, Mackay CE. Differential effects of the APOE genotype on brain function across the lifespan. Neuroimage. 2011; Jan 54:602-10.
19. Dean DC, Jerskey BA, Chen K, Protas H, Thiyyagura P, Roontiva A, O'Muircheartaigh J, Dirks H, Waskiewicz N, Lehman K, Siniard AL, Turk MN, Hua X, Madsen SK, Thompson PM, Fleisher AS, Huentelman MJ, Deoni SCL, Reiman EM. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 2014; Jan 71:11-22.
20. Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012; Mar 2:a006312.
21. Wolf AB, Valla J, Bu G, Kim J, LaDu MJ, Reiman EM, Caselli RJ. Apolipoprotein E as a ß-amyloid-independent factor in Alzheimer's disease. Alzheimers. Res. Ther. 2013; Jan 5:38.
22. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993; Sep 342:697-9.
23. Payami H, Montee KR, Kaye JA, Bird TD, Yu CE, Wijsman EM, Schellenberg GD. Alzheimer's disease, apolipoprotein E4, and gender. JAMA. 1994; May 271:1316-7.
24. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 278:1349-561997.
25. Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, Rosen HJ, Miller BL, Kramer JH, Greicius MD. Gender modulates the APOE e4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. JNeurosci. 2012; Jun 32:8254-62.
26. Fortea J, Sala-Llonch R, Bartrés-Faz D, Bosch B, Lladó A, Bargalló N, Molinuevo JL, Sánchez-Valle R. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J. Alzheimers. Dis. 2010; Jan 22:909-22.
27. Wolf AB, Caselli RJ, Reiman EM, Valla J. APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. NeurobiolAging. 2013; Apr 34:1007-17.
28. Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, Sánchez-Saudinos M-B, Sala I, Antón-Aguirre S, González S, Medrano S, Pegueroles J, Morenas E, Clarimón J, Blesa R, Lleó A. Cerebrospinal Fluid ß-Amyloid and Phospho-Tau Biomarker Interactions Affecting Brain Structure in Preclinical Alzheimer Disease. AnnNeurol. 2014; May :1-8.
29. Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar ß-amyloid, reduces cerebral glucose metabolism in normal aging. JNeurosci. 2012; Dec 32:18227-33.
30. Johnson SC, Christian BT, Okonkwo OC, Oh JM, Harding S, Xu G, Hillmer AT, Wooten DW, Murali D, Barnhart TE, Hall LT, Racine AM, Klunk WE, a Mathis C, Bendlin BB, Gallagher CL, Carlsson CM, a Rowley H, Hermann BP, Dowling NM, Asthana S, a Sager M. Amyloid burden and neural function in people at risk for Alzheimer's Disease. NeurobiolAging. 2014; Mar 35:576-84.
31. Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Aß plaques in a mouse model of Aß deposition. JNeuroinflammation. 2014; Jan 11:111.
32. Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N, Green S, Hendrickson B, Van Eldik LJ, LaDu MJ. APOE -modulated Aß-induced neuroinflammation in Alzheimer's disease: current landscape, novel data and future perspective. JNeurochem. 2015; Feb.
33. Sperling R, Aisen P, Beckett L. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups workgroups on diagnostic guidelines for Alzheimer's disease. 2011; May 7:280-92.
34. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010; Nov 9:1118-27.
35. Pletnikova O, Rudow G, Hyde T, Kleinman JE, Ali S, Bharadwaj R, Gangadeen S, Crain B, Fowler D, Rubio A, Troncoso J. Alzheimer lesions in the brains of young subjects. Cogn. Behav. Neurol. 2015; In press.
36. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee V M-Y, Trojanowski JQ, Initiative ADN. Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects. AnnNeurol. 2009; Apr 65:403-413.
37. Landau S, Jagust W. UC Berkeley FDG MetaROI methods. Alzheimer's Dis. Neuroimaging Initiat. 2011.
38. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000; Sep 97:11050-5.